|
2.2.1 Thiazides and related diuretics |
||
|
Bendroflumethiazide tablets 2.5mg, 5mg |
F |
|
|
Metolazone tablets 5mg |
F |
|
In the treatment of hypertension, doses of bendroflumethiazide in excess of 2.5mg daily are not usually necessary and may increase the incidence of side -effects.
Metolazone produces a synergistic diuresis when added to loop diuretic therapy and can be very effective if the loop diuretic alone has not proved effective. However, the resulting diuresis can be profound and patients should be carefully monitored for hypokalaemia and hyponatraemia.
|
2.2.2 Loop diuretics |
||
|
Bumetanide injection 2mg/4ml |
F |
|
|
Bumetanide liquid 1mg/5ml |
F |
|
|
Bumetanide tablets 1mg, 5mg |
F |
|
|
Furosemide injection 20mg/2ml, 50mg/5ml |
F |
|
|
Furosemide injection 250mg/5ml |
F |
|
|
Furosemide liquid 5mg/5ml, 20mg/5ml |
F |
|
|
Furosemide tablets 20mg, 40mg, 500mg |
F |
|
|
2.2.3 Potassium-sparing diuretics |
||
|
Amiloride oral solution 5mg/5ml |
F |
|
|
Amiloride tablets 5mg |
F |
|
|
Eplerenone tablets 25mg, 50mg |
F |
Cardiac failure following MI |
|
Spironolactone tablets 25mg, 50mg, 100mg |
F |
|
2.2.4 Potassium-sparing diuretics with other diuretics |
||
|
Burinex A (Bumetanide 1mg, amiloride 5mg) tablets |
F |
|
|
Co-amilofruse 5/40 tablets (Frumil) |
F |
Compound diuretic preparations are more expensive in the community than their components administered seperately. They are most suitable for patients whose drug treatment is stabilised and in whom there may be a compliance benefit from prescribing one product rather than two.
Patients on diuretic therapy do not necessarily require routine potassium supplementation. Those patients who experience hypokalaemia require potassium supplementation at therapeutic dosages and may require the addition of a potassium-sparing diuretic into their drug treatment. Compound preparations of diuretics with potassium (e.g. Burinex K) do not contain sufficient potassium to be of therapeutic benefit.